Health Care Sector Equities Technical Notes -- Research on ResMed, NuVasive, EnteroMedics, and Globus Medical
PR Newswire - Tue May 13, 12:00PM CDT
On Monday, May 12, 2014, the NASDAQ Composite ended at 4,143.86, up 1.77%, the Dow Jones Industrial Average finished the day 0.68% higher at 16,695.47, and the S&P 500 closed at 1,896.65, up 0.97%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 675.29, up 1.04%, and the index has advanced 4.74% in the last one month. Investor-Edge has initiated coverage on the following equities: ResMed Inc. (NYSE: RMD), NuVasive Inc. (NASDAQ: NUVA), EnteroMedics Inc. (NASDAQ: ETRM) and Globus Medical Inc. (NYSE: GMED). Free technical research on RMD, NUVA, ETRM and GMED can be downloaded upon signing up at:
EnteroMedics Reports First Quarter 2014 Financial Results
Marketwire - Wed Apr 30, 6:01AM CDT
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced financial results for the three months ended March 31, 2014.
EnteroMedics to Host First Quarter 2014 Financial Results and Business Update Conference Call
Marketwire - Wed Apr 23, 3:02PM CDT
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that it will host a conference call on Wednesday, April 30, 2014 at 11:00 AM Eastern Time to discuss financial results for the first quarter ended March 31, 2014 and to provide a business update.
Health Care Stocks Technical Data -- Research on St Jude Medical, EnteroMedics, Zimmer Holdings, and Varian Medical Systems
PR Newswire - Mon Apr 14, 7:00AM CDT
On Friday, April 11, 2014, the NASDAQ Composite ended at 3,999.73, down 1.34%, the Dow Jones Industrial Average declined 0.89%, to finish the day at 16,026.75, and the S&P 500 closed at 1,815.69, down 0.95%. The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 644.74, down 1.07%, and the same has fallen by 2.21% in the previous three trading sessions. Investor-Edge has initiated coverage on the following equities: St Jude Medical Inc. (NYSE: STJ), EnteroMedics Inc. (NASDAQ: ETRM), Zimmer Holdings Inc. (NYSE: ZMH) and Varian Medical Systems Inc. (NYSE: VAR). Free technical research on STJ, ETRM, ZMH and VAR can be downloaded upon signing up at:
EnteroMedics Inc. Appoints Mark Bullivant as Vice President of Marketing
Marketwire - Wed Apr 09, 6:01AM CDT
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, is pleased to announced that Mark Bullivant has joined the organization as Vice President of Marketing. He will report to Greg S. Lea, Senior Vice President, Chief Financial Officer and Chief Operating Officer. Most recently, Mr. Bullivant was Vice President of Global Marketing and International Sales at Terumo Heart Inc., a subsidiary of Terumo Corporation where he was responsible for developing strategic sales and marketing plans with focus on expanding the business in US and International markets. Mark brings 20 years of product management experience in both the medical and surgical fields.
EnteroMedics Announces the FDA Has Rescheduled the Advisory Committee Meeting Date to June 17, 2014 for Review of Maestro(R) Rechargeable System
Marketwire - Mon Mar 10, 6:00AM CDT
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that the U.S. Food and Drug Administration's Office of Device Evaluation has rescheduled a meeting of the Center for Devices and Radiologic Health's (CDRH) Advisory Committee for Tuesday, June 17, 2014 to review the Maestro(R) System delivering VBLOC(R) vagal blocking therapy as a treatment for morbid obesity. The prior meeting date presented a significant scheduling conflict for the CDRH.
Trend Report: 7 Insider And Hedge Fund Stock Picks To Consider
at The Street - Fri Feb 28, 4:35PM CST
Mary-Lynn Cesar, Kapitall: Insider and hedge fund stock picks don't always overlap, but when they do it makes for an [...]
5 Stocks Poised for Breakouts
at The Street - Fri Feb 28, 12:53PM CST
These stocks look ready to break out and trade higher from current levels.
European Foundations Directory 2013
M2 - Wed Feb 26, 3:17AM CST
This comprehensive new directory lists every major national and international foundations, NGOs and other charitable and grant-making organizations located on the entire European continent.
EnteroMedics to Present at the Cowen and Company 34th Annual Health Care Conference
Marketwire - Tue Feb 25, 6:01AM CST
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that Mark B. Knudson, Ph.D., EnteroMedics' President and Chief Executive Officer, is scheduled to present at the Cowen and Company 34th Annual Health Care Conference on March 5, 2014 at 10:00 am Eastern Time at the Boston Marriott Copley Place in Boston, MA.
Guangdong Taiantang 2013 Net Up 51%
SinoCast - Tue Feb 25, 4:57AM CST
Guangdong Taiantang Pharmaceutical Co., Ltd. (SZSE: 002433) revealed operating revenue of CNY 785 million in 2013, rising 51.61% from a year earlier. Net profit attributable to shareholders reached CNY 133 million, hiking 50.93%. Operational cash flow was negative CNY 142 million, in contrast to CNY 61.1475 million a year ago. Basic EPS were CNY 0.48.
Hot Stock: EnteroMedics, Shares Gain 6.9% (ETRM)
Comtex SmarTrend(R) - Wed Feb 12, 10:11AM CST
EnteroMedics (NASDAQ:ETRM) is one of today's best performing low-priced stocks, up 6.9% to $2.31 on 2.2x average daily volume. Thus far today, EnteroMedics has traded 2.3 million shares, vs. average volume of 1.1 million shares per day. The stock has outperformed the Dow (6.9% to the Dow's -0.2%) and outperformed the S&P 500 (6.9% to the S&P's -0.0%) during today's trading.
EnteroMedics Reports Fourth Quarter 2013 Financial Results
Marketwire - Wed Feb 12, 6:05AM CST
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced financial results for the three and twelve months ended December 31, 2013.
EnteroMedics Announces Food and Drug Administration Advisory Committee Meeting Date for Review of the Maestro(R) Rechargeable System for the Treatment of Obesity
Marketwire - Wed Feb 12, 6:01AM CST
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that the U.S. Food and Drug Administration's Office of Device Evaluation has scheduled a meeting of the Center for Devices and Radiologic Health's (CDRH) Advisory Committee on Thursday, May 29, 2014 to review the Maestro(R) System delivering VBLOC(R) vagal blocking therapy as a treatment for morbid obesity. The CDRH Advisory Committee is an independent panel of clinical and scientific experts that helps evaluate medical devices for safety and efficacy and makes recommendations regarding Benefit-Risk to the FDA.
RaceRender Software Brings High-Tech Data Overlays to Action Cameras
PR Newswire - Tue Feb 11, 7:30AM CST
RaceRender LLC has released the latest generation of its popular video + data overlay software for Microsoft Windows® and Apple Mac OS X®. RaceRender, now in Version 3, enables users to create high-tech sports and racing videos with GPS telemetry overlays and many other data visualizations, as well as multiple-camera picture-in-picture capabilities.
EnteroMedics (ETRM) Jumps: Stock Adds 7.8% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 03, 8:39AM CST
EnteroMedics Inc. was a big mover last session, as its shares rose almost 8% on the day.
Traders Get Bullish on Shares of EnteroMedics, Shares Up 11.8% (ETRM)
Comtex SmarTrend(R) - Thu Jan 02, 11:47AM CST
EnteroMedics (NASDAQ:ETRM) is one of today's best performing low-priced stocks, up 11.8% to $2.28 on 1.1x average daily volume. EnteroMedics has traded 2.4 million shares thus far today, vs. average volume of 2.2 million shares per day. The stock has outperformed the Dow (11.8% to the Dow's -0.8%) and outperformed the S&P 500 (11.8% to the S&P's -0.9%) during today's trading.
Stock to Watch: EnteroMedics Down 8.6% (ETRM)
Comtex SmarTrend(R) - Fri Dec 06, 10:41AM CST
EnteroMedics (NASDAQ:ETRM) is one of today's worst performing low-priced stocks, down 8.6% to $1.91 on 1.1x average daily volume. Thus far today, EnteroMedics has traded 1.7 million shares, vs. average volume of 1.6 million shares per day. The stock has underperformed the Dow (-8.6% to the Dow's 1.0%) and underperformed the S&P 500 (-8.6% to the S&P's 0.9%) during today's trading.
Proposed Offering and Amendments, Patents, Results, and Announcements by Healthcare Companies - Research Report on Forest Laboratories, OncoMed, EnteroMedics, Cadence, and Amarin
PR Newswire - Fri Dec 06, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Forest Laboratories Inc. (NYSE: FRX), OncoMed Pharmaceuticals, Inc. (NASDAQ: OMED), EnteroMedics, Inc. (NASDAQ: ETRM), Cadence Pharmaceuticals Inc. (NASDAQ: CADX), and Amarin Corporation plc (NASDAQ: AMRN). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Biotech Stock Mailbag: Enteromedics, ARCA Biopharma, Keryx Pharma
at The Street - Fri Dec 06, 5:00AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.